

## REFERENCES

- ALBRECT, C.F., KRUGER, P.B., SMIT, B.J., FREESTONE, M., GOUWS, L., MILLER, R. & VAN JAARSVELD, P.P. 1995. The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial. *South African Medical Journal*, 85, 861-865.
- ALBRECHT, C.F., THERON, E.J. & KRUGER, P.B. 1995. Morphological characterisation of the cell-growth inhibitory activity of rooperol and pharmacokinetic aspects of hypoxoside as an oral prodrug for cancer therapy. *South African Medical Journal*, 85, 853-860.
- ANON. 2000. Plant fats proven to bolster the immune system. *Internet*:  
<http://www.naturaltrends.com/prod03.htm>. Access: 31 Jan 2000.
- ARNOLD, T.H. & DE WET, B.C. 1993. *Plants of Southern Africa: names and distribution*. Pretoria: National Botanical Institute.
- BAYNE, C.W., DONNELLY, F., ROSS, M. & HABIB, F.K. 1999. *Serenoa repens* (Permixon®): A 5 $\alpha$ -reductase types I and II inhibitor – New evidence in a coculture model of BPH. *The Prostate*, 40, 232-241.
- BERGES, R.R., WINDELER, J. & TRAMPISCH, H. 1995. Randomised placebo-controlled double blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. *Lancet*, 345, 1529-1532.
- BOUIC, P.J.D. 1997. Immunomodulation in HIV/AIDS: The Tygerberg /Stellenbosch University Experience. *AIDS Bulletin*, 6 (3), 18-20.
- BOUIC, P.J.D. & LAMPRECHT, J.H. 1999. Plant sterols and sterolins: A review of their immunomodulating properties. *Alternative Medicine Review*, 4 (3), 170-177.
- BOUIC, P.J.D., ETSEBETH, S., LIEBENBERG, R.W., ALBRECHT, C.F., PEGEL, K. & VAN JAARSVELD, P.P. 1997. Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation: implications for their use as an immunomodulatory vitamin combination. *International Journal of Immunopharmacology*, 18 (12), 693-700.
- CANNELL, R.J.P. 1998. *Natural products isolation*. Totowa: Humana Press Inc.
- CARRARO, J.C., RAYNAUD, J.P., KOCH, G., CHISHOLM, G.D., DI SILVERIO, F., TEILLAC, P., DA SILVA, F.C., CAUQUIL, J., CHOPIN, D.K., HAMDY, F.C., HANUS, M., HAURI, D., KALINTERIS, A., MARENCAK, J., PERIER, A. & PERRIN, P. 1996. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. *Prostate*, 29 (4), 231-240.

- CHATELAIN, C., AUTET, W. & BACKMAN, F. 1999. Comparison of once and twice daily dosage forms of *Pygeum africanum* extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. 1999. *Urology*, 54 (3), 473-478.
- DE SILVERIO, F., MONTI, S., SCIARRA, A., VARASANO, P.A., MARTINI, C., LANZARA, S., D'ERAMO, G., DI NICOLA, S. & TOSCANO, V. 1998. Effects of long-term treatment with *Serenoa repens* (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. *The Prostate*, 37, 77-83.
- DONALD, P.R., LAMPRECHT, J.H., FREESTONE, M., ALBRECHT, C.F., BOUIC, P.J.D., KOTZE, D. & VAN JAARSVELD, P.P. 1997. A randomised placebo-controlled trial of the efficacy of beta-sitosterol and its glucoside as adjuvants in the treatment of pulmonary tuberculosis. *The International Journal of Tuberculosis and Lung Disease*, 1 (5), 518-522.
- DYER, R.G., HETHERINGTON, C.S., ALBERTI, K.G.M.M. & LAKER, M.F. 1995. Simultaneous measurement phytosterols (campesterol and  $\beta$ -sitosterol) and 7-ketocholesterol in human lipoproteins by capillary column gas chromatography. *Journal of Chromatography B*, 663, 1-7.
- ELOFF, J.N. 1998. The presence of antibacterial compounds in *Anthocleista grandiflora* (Loganiaceae). *South African Journal of Botany*, 64, 209-212.
- ELOFF, J.N. 1999. A preliminary investigation into the composition of the compounds present in Immunochoice® and Moducare®. Confidential report to BIOMOX PHARMACEUTICALS (Pty) Ltd.
- EMARA, L.H., EL-MENSHAWI, B.S. & ESTEFAN, M.Y. 1999. Bioavailability of  $\beta$ -sitosterol from *Pygeum africanum* extract in humans. *Pharmaceutical and Pharmacological Letters*, 9 (2), 80-83.
- FITZPATRICK, J.M. 1999. Phytotherapy for treatment of benign prostatic hyperplasia: case not proven. *Urology*, 53, 462-464.
- GERBER, G.S., ZAGAJA, G.P., BALES, G.T., CHODAK, G.W. & CONTRERAS, B.A. 1998. Saw palmetto (*Serenoa repens*) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. *Urology*, 51 (6), 1003-1007.
- GOEPEL, M., HECKER, U., KREGE, S., RUBBEN, H. & MICHEL, M.C. 1999. Saw palmetto extracts potently and noncompetitively inhibit human  $\alpha_1$ -adrenoceptors *in vitro*. *The Prostate*, 38, 208-215.
- GOULD, R.G., JONES, R. J., LEROY, G.V., WISSLER, R.W. & TAYLOR, C.B. 1969. Absorbability of  $\beta$ -sitosterol in humans. *Metabolism*, 18 (8), 652- 662.

- GUPTA, M.B., NATH, R., SRIVASTAVA, N., SHANKER, K., KISHOR, K. & BHARGAVA, K.P. 1988. Anti-inflammatory and antipyretic activities of  $\beta$ -sitosterol. *Journal of Medicinal Plant Research*, 39, 157-163.
- HAHN-DEINSTROP, E. 2000. *Applied thin layer chromatography*. Weinheim: Wiley-VCH.
- HARDMAN, J.G. & LIMBIRD, L.E. 1996. *Goodman and Gilman's pharmacological basis of therapeutics*. 9<sup>th</sup> ed. New York: The McGraw-Hill Companies, Inc.
- HOUGHTON, P.J. & RAMAN, A. 1998. *Laboratory handbook for the fractionation of natural extracts*. London: Chapman & Hall.
- INGRAHAM, J.L. & INGRAHAM, C.A. 1995. *Introduction to microbiology*. Belmont: Wadsworth Publishing Company.
- IVORRA, M.D., D'OCÓN, M.P., PAYA, M. & VILLAR, A. 1988. Antihyperglycemic and insulin-releasing effects of  $\beta$ -sitosterol 3- $\beta$ -D-glucoside and its aglycone,  $\beta$ -sitosterol. *Archives Internationales de Pharmacodynamie et de Therapie*, 296, 224-231.
- KADOW, C. & ABRAMS, P.H. 1986. A double-blind trial of the effect of beta-sitosterol glucoside (WA184) in the treatment of benign prostatic hyperplasia. *European urology*, 12, 187-189.
- KLIPPEL, K.F., HILTL, D.M. & SCHIPP, B. 1997. A multicentric, placebo-controlled, double-blind clinical trial of  $\beta$ -sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. *British Journal of Urology*, 80, 427-432.
- KOCH, H.P. & BROSCHE-STARZENGRUBER, N.B. 1991. Biopharmaceutical investigation of hypoxoside, a natural antitumor compound from plant origin. *Journal of Biopharmaceutical Sciences*, 2 (4), 305-318.
- KROSCWITZ, J.I. & HOWE-GRANT, M. 1997. *Kirk-Othmer encyclopedia of chemical technology*. 4<sup>th</sup> ed. New York: John Wiley & Sons, Inc.
- KRUGER, P.B., ALBRECHT, C.F., LIEBENBERG, R.W., VAN JAARSVELD, P.P. 1994. Studies on hypoxoside and rooperol analogues from *Hypoxis rooperi* and *Hypoxis latifolia* and their biotransformation in man by using high-performance liquid chromatography with in-line sorption enrichment and diode-array detection. *Journal of Chromatography B*, 662, 71-78.
- LEES, A.M., MOK, H.Y.I., LEES, R.S., MCCLUSKEY, M.A. & GRUNDY, S.M. 1977. Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. *Atherosclerosis*, 28, 325-338.
- LEVIN, R.M., LEVIN, S.S., ZHAO, Y. & BUTTYAN, R. 1997. Cellular and molecular aspects of bladder hypertrophy. *European Urology*, 32 (1), 15-21.

- LEVIN, R.M., RIFFAUD, J.P., BELLAMY, F., ROHRMANN, D., HABIB, M., KRANOPOLSKY, L., ZHAO, Y. & WEIN, A.J. 1996. Protective effect of Tadenan® of bladder function secondary to partial outlet obstruction. *The Journal of Urology*, 155 (4), 1466-1470.
- LOWE, F.C. & FAGELMAN, E. 1999. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. *Urology*, 53, 671-678.
- LOWE, F.C., DREIKORN, K., BORKOWSKI, A., BRAECKMAN, J., DENIS, L., FERRARI, P., GERBER, G., LEVIN, R., PERRIN, P. & SENGE, T. 1998. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. *The Prostate*, 37, 187-193.
- LUND, W. 1994. *The pharmaceutical codex*. 12<sup>th</sup> ed. London: Pharmaceutical Press.
- MARKS, L.S. & TYLER, V.E. 1999. Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. *Urology*, 53, 457-461.
- MASOHAN, A. & BHATIA, V.K. 1996. HPLC in the analysis of steroidal compound mixtures as applied to biocrudes. *Journal of Chromatographic Science*, 34, 550-555.
- MCALISTER, B.G. & VAN STADEN, J. 1995. Effect of artificially induced stress conditions on the growth of the medicinal plant *H. hemerocallidea*. *South African Journal of Botany*, 61 (2), 85-89.
- NGUYEN, T.T. 1999. The cholesterol-lowering action of plant stanol esters. *Journal of nutrition*, 129 (12), 2109-2112.
- NICOLETTI, M., PIERETTI, S., CAPASSO, A. & GALEFFI, C. 1996. Analgesic effects induced by hypoxoside, a norlignan glucoside from *Hypoxis* spp. *Phytotherapy Research*, 10, 398-401.
- PEGEL, K.H., 1997. The importance of sitosterol and sitosterolin in human and animal nutrition. *South African Journal of Science*, 93, 263-267.
- PHILLIPS, K.M., RUGGIO, D.M. & BAILEY, J.A. 1999. Precise quantitative determination of phytosterols, stanols, and cholesterol metabolites in human serum by capillary gas-liquid chromatography. *Journal of Chromatography B*, 732, 17-29.
- PLATEL, S.B., HONDA, A. & SALEN, G. 1998. Sitosterolemia: exclusion of genes involved in reduced cholesterol biosynthesis. *Journal of Lipid Research*, 39, 1055-1061.
- QUIRKE, J.M.E., TIGANI, R.A. & DILLEY, A.S. 1998. Derivatization for electrospray ionization mass spectrometry. Three electrochemically ionizable derivatives. *Analytical Chemistry*, 70, 1544-1554.
- RHODES, L., PRIMKA, R.L., BERMAN, C., VERGULT, G., GABRIEL, M., MALICE, M.P. & GIBELIN, B. 1993. Comparison of finasteride (Proscar®), a 5 $\alpha$ -reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 $\alpha$ -reductase inhibition. *The Prostate*, 22, 43-51.

- RITSCHER, W.A., KASTNER, U. HUSSAIN, A.S. & KOCH, H.P. 1990. Pharmacokinetics and bioavailability of  $\beta$ -sitosterol in the beagle dog. *Arzneimittel-Forschung/Drug Resistance*, 40 (4), 463-468.
- SALEN, G., AHRENS, E.H. & GRUNDY, S.M. 1970. Metabolism of  $\beta$ -sitosterol in man. *The Journal of Clinical Investigation*, 49, 952-967.
- SALEN, G., SHORE, V., TINT, G.S., FORTE, T., SHEFER, S., HORAK, I., HORAK, E., DAYAL, B., NGUYEN, L., BATTI, A.K., LINDGREN, F.T. & KWITEROVICH, P.O. 1989. Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. *Journal of Lipid Research*, 30, 1319-1330.
- SCHULZ, V., HANSEL, R. & TYLER, V.E. 1998. *Rational Phytotherapy. A physician's guide to herbal medicine*. Berlin: Springer-Verlag.
- SEGARS, L.W., 1999. Saw palmetto extracts for benign prostatic hyperplasia. *Journal of Family Practice*, 48 (2), 88.
- SKOOG, D.A., WEST, D.M. & HOLLER, F.J. 1996. *Fundamentals of analytical chemistry*. 7<sup>th</sup> ed. Forth Worth: Saunders College Publishing.
- SMIT, B.J., ALBRECHT, C.F., LIEBENBERG, R.W., KRUGER, P.B., FREESTONE, M., GOUWS, L., THERON, E., BOUIC, P.J.D., ETSEBETH, S. & VAN JAARVELD, P.P. 1995. A phase I trial of hypoxoside as an oral prodrug for cancer therapy - absence of toxicity. *South African Medical Journal*, 85, 865-870.
- SNYDER, L.R. & KIRKLAND, J.J. 1979. *Introduction to modern liquid chromatography*. 2<sup>nd</sup> ed. New York: John Wiley & Sons, Inc.
- STAHL, E. 1969. *Thin-layer chromatography*. 2<sup>nd</sup> ed. Berlin: Springer-Verlag.
- STECHE, P.G., WINDHOLZ, M. & LEAHY, D.S. 1968. *The Merck Index*. 8<sup>th</sup> ed. Rahway: Merck & Co., Inc.
- TOSCANO, V. & HORTON, R. 1987. Circulating dihydrotestosterone may not reflect peripheral formation. *Journal of Clinical Investigations*, 79, 1653-1658.
- TOTH, I., SZECHI, M., JULESZ, J., FAREBIN, I. & BEHNKE, B. 1996. *In vitro* inhibition of testicular  $\Delta^5$ - $3\beta$ -hydroxysteroid dehydrogenase and prostatic  $5\alpha$ -reductase in rats and humans by Strogen forte extract. *International Urology and Nephrology*, 8 (3), 337-348.
- VAN WYK, B.E., VAN OUDTSHOORN, B. & GERICKE, N. 1997. *Medicinal plants of South Africa*. Pretoria: Briza Publications.
- VANDERHAEGHE, L.R. & BOUIC, P.J.D. 1999. *The Immune System Cure*. Hermanus: Pyramid Publishers.


- VON ZAHN, P. & RHEINHOLZ, I. 1980. *The many faces of research*. Vienna: Econ Verlag.
- WEISSER, H., TUNN, S., BEHNKE, B. & KRIEG, M. 1996. Effects of the *Sabal serrulata* extract IDS 89 and its subfractions on 5 $\alpha$ -reductase activity in human benign prostatic hyperplasia. *The Prostate*, 28, 300-306.
- WILT, T.J., ISHANI, A., STARK, G., MACDONALD, R., LAU, J. & MULROW, C. 1998. Saw palmetto extracts for treatment of benign prostatic hyperplasia. *The Journal of the American Medical Association*, 280 (18), 1604-1609.
- YABLONSKY, F., NICOLAS, V., RIFFAUD, J.P. & BELLAMY, F. 1997. Antiproliferative effect of *Pygeum africanum* extract on rat prostatic fibroblasts. *The Journal of Urology*, 157 (6), 2381-2387.





Basic Frequency: 400 MHz


Line Width: 0.10 Hz








Basic Frequency: 400 MHz  
Line Width: 0.10 Hz





Basic Frequency: 400 MHz

Line Width: 0.10 Hz



Rooi Kol/Acetone-D6/1H


Current Data Parameters  
 NAME JCRooiKol  
 EXPNO 1  
 PROCNO 1







F2 - Acquisition Parameters  
 Date\_ 20010603  
 Time 11.03  
 INSTRUM spect  
 PROBHD 5 mm QNP 1H Z-  
 PULPROG zg30  
 TD 65536  
 SOLVENT Acetone  
 NS 87  
 DS 2  
 SWH 10330.578 Hz  
 FIDRES 0.157632 Hz  
 AQ 3.1720407 sec  
 RG 362  
 DW 48.400 usec  
 DE 6.00 usec  
 TE 300.0 K  
 D1 1.00000000 sec

==== CHANNEL f1 =====  
 NUC1 1H  
 P1 10.55 usec  
 PL1 -3.00 dB  
 SF01 500.1330885 MHz


F2 - Processing parameters  
 SI 32768  
 SF 500.1300071 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

1D NMR plot parameters  
 CX 20.00 cm  
 CY 0.00 cm  
 F1P 8.953 ppm  
 F1 4477.57 Hz  
 F2P -0.307 ppm  
 F2 -153.37 Hz  
 PPMCM 0.46297 ppm/cm  
 HZCM 231.54744 Hz/cm





Rooi Kol/Acetone-D6/13C



Current Data Parameters  
NAME JCRooiKo  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters

Date\_ 20010603  
Time 11.15  
INSTRUM spect  
PROBHD 5 mm GNP 1H Z-  
PULPROG zgpg30  
TD 65536  
SOLVENT Acetone  
NS 56974  
DS 4  
SWH 30030.029 Hz  
FIDRES 0.458222 Hz  
AQ 1.0912410 sec  
RG 1448.2  
DW 16.650 usec  
DE 6.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
d11 0.03000000 sec  
d12 0.00002000 sec

===== CHANNEL f1 =====  
NUC1 13C  
P1 10.00 usec  
PL1 8.00 dB  
SF01 125.7703143 MHz









===== CHANNEL f2 =====  
CPOPRG2 waltz16  
NUC2 1H  
PCPD2 100.00 usec  
PL2 -3.00 dB  
PL12 17.50 dB  
PL13 17.50 dB  
SF02 500.1320005 MHz

F2 - Processing parameters

SF 32768  
SF 125.7577390 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

1D NMR plot parameters

CX 20.00 cm  
CY 0.00 cm  
F1P 165.737 ppm  
F1 20842.73 Hz  
F2P -2.932 ppm  
F2 -368.69 Hz  
PPMCM 8.43345 ppm/cm  
HZCM 1060.57104 Hz/cm






## **APPENDIX B**

### **CONTENTS**

**Ethics Committee approval of the protocol of the proposed clinical trial (S83/2000)**

**Ethics Committee approval of amendment to the protocol (Amendment to S83/2000)**



DEPARTMENT  
OF  
HEALTH

DEPARTEMENT  
VAN  
GESONDHEID

Tel: (012) 354 1560  
Fax/Faks: (012) 354 1831  
Ref/Verw: Ethics Committee  
Enquiries/Navrae: Dr R Sommers  
Ward 4 Room 19  
Date : 20/07/2000

**Number** : S83/2000  
**Title** : Protocol of proposed clinical trial, including pilot study, to determine the absorption of sterols and steroplins in human volunteers.  
**Investigator** : A C Retief; Department of Pharmacology;  
Prof J R Snyman; Dept Pharmacology  
Pretoria Academic Hospital; Pretoria.

**This Protocol and Informed Consent has been considered by the Ethics Committee, Faculty of Medicine, Univ.of Pretoria and Pretoria Academic Hospitals on 19/07/2000 and found to be acceptable.**

Dr J.E.Davel	(female) MBChB:Hospital Superintendent
Prof A.P.du Toit	BA;DiplTheo; BA (Hons);MA;DPhil:Philosopher
Prof C.I. Falkson	(female)MBChB;M.Med(Int);MD;Med. Oncologist
Prof G. Falkson	CHAIRPERSON; MBChB;M.Med(Int);MD;OSG: Medical Oncologist
Mrs C Gerber	(female)BA(FineArts);Architectural Draughting (Boston House College Pta)
Prof S.V. Grey	(female)BSc(Hons);MSc; DSc :Deputy Dean
Mrs R Jooste	(female) Dip. Pharm; M Pharm; Pharmacist.
Dr V.O.L. Karusseit	MBChB;MFGP(SA);M.Med(Chir); FCS (SA): Surgeon
Dr S.Khan	(female)MB.BCh.; Med.Adviser (Gauteng Dept.of Health).
Ms B.C.F.Magardie	(female) BCur:Matron/Senior Nursing-Sister
Miss B Mullins	(female) BscHons;Teachers Diploma;
Dr P.Z Njongwe	(female)MBChB ;D.P.H;DTMtH; DOH ;F.F.C.H(CM) S.A.Chief Med.Super of Pretoria Academic Hospital.
Snr Sr J. Phatoli	(female) BCur(Et.AI)Senior Nursing-Sister
Prof H.W. Pretorius	MBChB;M.Med (Psych) MD: Psychiatrist
Prof P. Rheeder	MBChB;MMed(Int);LKI(SA);MSc (KLIN.EPI): Specialist Physician
Prof M.M.S.Smuts	(female) BVSc; DVSc
Prof De K.Sommers	BChB; HDD; MBChB; MD: Pharmacologist
Dr R Sommers	SECRETARIAT (female)MBChB; M.med (Int);MPhar.Med;
Prof FFW van Oosten	BA; LLB ; LLD ;LLD ;Head of Department of Public Law and Prof in Criminal Law and Medical Law

**Student Ethics Sub-Committee**

Mrs E Ahrens	(female)B.Cur;
Prof S.V. Grey	(female)BSc(Hons);MSc ;DSc :Deputy Dean
Prof P. Rheeder	MBChB;MMed(Int);LKI(SA);MSc (KLIN.EPI): Specialist Physician
Dr R Sommers	SECRETARIAT (female)MBChB; M.med (Int); MPharMed;
Dr C van der Westhuizen	(female) D.Cur; M.Ed.

**PROF G FALKSON;**

MBChB;M.Med(Int);MD;OSG: Medical Oncologist  
CHAIRPERSON of the Ethics Committee at Pretoria Academic Hospital;

**PROF P RHEEDER;**

BChB;MMed(Int);LKI(SA);MSc (KLIN.EPI):Specialist Physician  
CHAIRPERSON of the Student Ethics Committee at P.A. H





DEPARTMENT  
OF  
HEALTH

DEPARTEMENT  
VAN  
GESONDHEID

Tel: (012) 354 1560

Fax/Faks: (012) 354 1831

Ref/Verw: Ethics Committee

Enquiries/Navrae: **Dr R Sommers**  
Ward 4 Room 19

**Date : 1/03/2001**

**Number :** Amendment to **S83/2000**

**Title :** Protocol of proposed clinical trial, including pilot study, to determine the absorption of sterols and sterolins in human volunteers.

**Investigator :** A C Retief; Department of Pharmacology;  
Prof J R Snyman; Dept Pharmacology  
Pretoria Academic Hospital; Pretoria.

**This Addendum has been considered by the Ethics Committee, Faculty of Medicine, Univ. of Pretoria and Pretoria Academic Hospitals on 28/02/2001 and found to be acceptable.**

Dr J.E.Davel	(female) MBChB:Hospital Superintendent
Prof A.P.du Toit	BA;DipITheo; BA (Hons);MA;DPhil:Philosopher
Prof S.V. Grey	(female)BSc(Hons);MSc; DSc :Deputy Dean
Mrs R Jooste	(female) Dip. Pharm; M Pharm; Pharmacist.
Dr V.O.L. Karusseit	MBChB;MFGP(SA);M.Med(Chir); FCS (SA): Surgeon
Dr S.Khan	(female)MB.BCh.; Med.Adviser (Gauteng Dept.of Health).
Miss B Mullins	(female) BScHons;Teachers Diploma;
Snr Sr J. Phatoli	(female) BCur(Et.Al)Senior Nursing-Sister
Prof H.W. Pretorius	MBChB;M.Med (Psych) MD: Psychiatrist
Prof P. Rheeder	MBChB;MMed(Int);LKI(SA);MSc (KLIN.EPI): Specialist Physician
Dr C F Slabber	MB BCh, FCP (SA) Acting Head; Dept Medical Oncology
Prof De K.Sommers	BChB; HDD; MBChB; MD: Pharmacologist
Dr R Sommers	SECRETARIAT (female)MBChB; M.med (Int);MPhar.Med;

**Student Ethics Sub-Committee**

Mrs E Ahrens	(female)B.Cur;
Prof S.V. Grey	(female)BSc(Hons);MSc ;DSc :Deputy Dean
Prof P. Rheeder	MBChB;MMed(Int);LKI(SA);MSc (KLIN.EPI): Specialist Physician
Dr R Sommers	SECRETARIAT (female)MBChB; M.med (Int); MPharMed;
Dr C van der Westhuizen	(female) D.Cur; M.Ed.

**PROF. P. RHEEDER;**

CHAIRPERSON of the Student Ethics Committee at P.A. H.  
BChB;MMed(Int);LKI(SA);MSc (KLIN.EPI):Specialist Physician